Novel γ-secretase modulators for the treatment of Alzheimer's disease: A review focusing on patents from 2010 to 2012

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 10, 2013, Pages 1349-1366

  Pettersson, Martin ^a   Stepan, Antonia F ^a   Kauffman, Gregory W ^a   Johnson, Douglas S ^a  

^a PFIZER INC   (United States)

Author keywords

secretase; A 42; Alzheimer's disease; APP; Modulator; Presenilin

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AVAGACESTAT; BIIB 042; CHF 5074; E 2012; EVP 0015962; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; IBUPROFEN; INDOMETACIN; JNJ 40418677; MITOPODOZIDE; NATURAL PRODUCT; NGP 555; SEMAGACESTAT; SPI 1802; SPI 1810; SULINDAC SULFIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; COGNITIVE DEFECT; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; ENZYME REGULATION; HIPPOCAMPUS; HUMAN; IC 50; LIPOPHILICITY; LONG TERM CARE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; REVIEW; SPATIAL MEMORY; TREATMENT RESPONSE; WORKING MEMORY;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARBOXYLIC ACIDS; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS; HUMANS; PATENTS AS TOPIC;

EID: 84884559939     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.821465     Document Type: Review

References (100)

1. De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and gamma-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006304
2. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10:698-712
3. Kreft AF, Martone R, Porte A. Recent advances in the identification of gammasecretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem 2009;52:6169-88
4. Imbimbo BP, Panza F, Frisardi V, et al. Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 2011;20:325-41
5. Sambamurti K, Greig NH, Utsuki T, et al. Targets for AD treatment: conflicting messages from gamma-secretase inhibitors. J Neurochem 2011;117:359-74
6. Schor NF. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 2011;69:237-9
7. Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012;69:1430-40
8. Crump CJ, Castro SV, Wang F, et al. BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry 2012;51:7209-11
9. Chavez-Gutierrez L, Bammens L, Benilova I, et al. The mechanism of gamma-secretase dysfunction in familial Alzheimer disease. EMBO J 2012;31:2261-74
10. McKee TD, Loureiro RM, Dumin JA, et al. An improved cell-based method for determining the gamma-secretase enzyme activity against both Notch and APP substrates. J Neurosci Methods 2013;213:14-21
11. Albright CF, Dockens RC, Meredith JE Jr, et al. Pharmacodynamics of selective inhibition of gamma-secretase by avagacestat. J Pharmacol Exp Ther 2013;344:686-95
12. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-16 (Pubitemid 33051236)
13. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta42 in vivo. J Clin Invest 2003;112:440-9 (Pubitemid 38063773)
14. Weggen S, Eriksen JL, Sagi SA, et al. Abeta42-lowering nonsteroidal antiinflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003;278:30748-54 (Pubitemid 36994581)
15. Takahashi Y, Hayashi I, Tominari Y, et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta42 generation. J Biol Chem 2003;278:18664-70 (Pubitemid 36799494)
16. Pettersson M, Kauffman GW, am Ende CW, et al. Novel gamma-secretase modulators: a review of patents from 2008 to 2010. Expert Opin Ther Pat 2011;21:205-26
17. Oehlrich D, Berthelot DJ, Gijsen HJ. gamma-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem 2011;54:669-98
18. Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. Curr Top Med Chem 2008;8:47-53 (Pubitemid 351791046)
19. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-64
20. Imbimbo BP, Del Giudice E, Colavito D, et al. 1-(3',4'-Dichloro-2- fluoro[1,1'- biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gammasecretase modulator, reduces brain betaamyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 2007;323:822-30 (Pubitemid 350146064)
21. Imbimbo BP, Frigerio E, Breda M, et al. Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects. Alzheimer Dis Assoc Disord 2012;doi.org/10.1097/WAD.0b013e3182622ace
22. Page RM, Baumann K, Tomioka M, et al. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-Associated presenilin mutations and gamma-secretase modulation. J Biol Chem 2008;283:677-83
23. Ohki Y, Higo T, Uemura K, et al. Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J 2011;30:4815-24
24. Crump CJ, Fish BA, Castro SV, et al. Piperidine acetic acid based gammasecretase modulators directly bind to presenilin-1. ACS Chem Neurosci 2011;2:705-10
25. Kounnas MZ, Danks AM, Cheng S, et al. Modulation of gamma-secretase reduces beta-Amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010;67:769-80
26. Hashimoto T, Ishibashi A, Hagiwara H, et al. E2012: A novel gamma-secretase modulator - pharmacology. Alzheimers Dement 2010;6(Suppl):S242
27. Portelius E, Van Broeck B, Andreasson U, et al. Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 2010;21:1005-12
28. Findeis MA, Schroeder F, McKee TD, et al. Discovery of a novel pharmacological and structural class of gamma-secretase modulators derived from the extract of Actaea racemosa. ACS Chem Neurosci 2012;3:941-51
29. Crump CJ, Johnson DS, Li YM. Development and mechanism of gammasecretase modulators for Alzheimer's disease. Biochemistry 2013;52:3197-216 cLogP (version 4.3). BioByte Corp
30. Ertl P, Rohde B, Selzer P. Fast Calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000;43:3714-17
31. Hattori K, Wakabayashi H, Tamaki K. Predicting key example compounds in competitors' patent applications using structural information alone. J Chem Inf Model 2008;48:135-42 (Pubitemid 351271058)
32. Hall A, Elliott RL, Giblin GM, et al. Piperidine-derived gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:1306-11
33. Hawkins J, Harrison DC, Ahmed S, et al. Dynamics of Abeta42 reduction in plasma, CSF and brain of rats treated with the gamma-secretase modulator. GSM-10h. Neurodegener Dis 2011;8:455-64
34. Li T, Huang Y, Jin S, et al. gamma- Secretase modulators do not induce Abeta-rebound and accumulation of beta- C-terminal fragment. J Neurochem 2012;121:277-86
35. Hussain I, Harrison DC, Hawkins J, et al. TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to gamma-secretase modulation and Abeta42 lowering by GSM-10h. Neurodegener Dis 2011;8:15-24
36. Mitani Y, Yarimizu J, Saita K, et al. Differential effects between gammasecretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 2012;32:2037-50
37. Mitani Y, Yarimizu J, Akashiba H, et al. Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Abeta42 without affecting other Abeta pools. J Neurochem 2013;125:465-72
38. Am Ende CW, Fish BA, Johnson DS, et al. Pfizer, Inc., USA. Aminocyclohexanes and aminotetrahydropyrans as gammasecretase modulators and their preparation and use for the treatment of neurological and psychiatric diseases. WO2011092611A1; 2011
39. Yamasaki S, Honjo E, Samizu K, et al. Astellas Pharma, Inc., Japan. Preparation of cycloalkane compounds as gammasecretase modulators. WO2012046771A1; 2012
40. Shapiro G, Chesworth R, EnVivo Pharmaceuticals, Inc., USA. Preparation of tetrasubstituted benzenes as gammasecretase modulators for treating Alzheimer's Disease. W02009086277A1; 2009
41. Rogers K, Felsenstein KM, Hrdlicka L, et al. Modulation of gamma-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol Neurodegener 2012;7:61
42. Ho C, Schering Corp., USA. Preparation of biphenyl derivatives as gammasecretase modulators. WO2009052341A1; 2009
43. Van Broeck B, Chen JM, Treton Y, et al. Chronic treatment with a novel gamma-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br J Pharmacol 2011;163:375-89
44. Peng H, Cuervo JH, Ishchenko A, et al. Biogen Idee Ma, Inc., USA. Preparation of carboxylic acid-containing compounds and derivatives thereof useful in treating Alzheimer's disease. WO2010138901A1; 2010
45. Xin Z, Peng H, Zhang A, et al. Discovery of 4-Aminomethylphenylacetic acids as gamma-secretase modulators via a scaffold design approach. Bioorg Med Chem Lett 2011;21:7277-80
46. Peng H, Talreja T, Xin Z, et al. Discovery of BIIB042, a potent, selective, and orally bioavailable gamma-secretase modulator. ACS Med Chem Lett 2011;2:786-91
47. Bulic B, Ness J, Hahn S, et al. Chemical biology, molecular mechanism and clinical perspective of gamma-secretase modulators in Alzheimer's disease. Current Neuropharmacology 2011;9:598-622
48. Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem 2008;8:54-61Available from: www.clinicaltrials.gov [Last accessed 15 May 2013] (Pubitemid 351791047)
49. Zhu Z, Greenlee W, Sun Z-Y, et al. Schering Corp., USA. Preparation of substituted alkenyloxadiazole derivatives and analogs as gamma-secretase modulators. WO2008137139A1; 2008
50. Sun ZY, Asberom T, Bara T, et al. Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious gamma-secretase modulators in vivo. J Med Chem 2012;55:489-502
51. Zhu Z, Greenlee W, Huang X, et al. Schering Corp., USA. Preparation of phenylhexahydroimidazopyridine derivatives and analogs as gammasecretase modulators. WO2008153793A2; 2008
52. Huang X, Zhou W, Liu X, et al. Synthesis and SAR studies of fused oxadiazines as gamma-secretase modulators for treatment of Alzheimer's disease. ACS Med Chem Lett 2012;3:931-5
53. Zhu Z, Greenlee W, Li H, et al. Schering Corp., USA. Heterocyclic compounds as gamma-secretase modulators and their preparation and use in the treatment of CNS diseases. WO2010056722A1; 2010
54. Li H, Qin J, Dhondi P, et al. The discovery of fused oxadiazepines as gamma-secretase modulators for treatment of Alzheimer's disease. Bioorg Med Chem Lett 2013;23:466-71
55. Huang X, Zhu Z, Greenlee WJ, et al. Schering Corp., USA. Heterocyclic fused pyridines as gamma secretase modulators and their preparation and use in the treatment of Alzhemier's diseases. WO2010147973A1; 2010
56. Huang X, Zhu Z, Greenlee WJ, et al. Schering Corp., USA. Heterocyclic fused pyridines as gamma secretase modulators and their preparation, and use in the treatment of Alzheimer's disease. WO2010147975A1; 2010
57. Zhu Z, Huang X, Palani A, et al. Schering Corp., USA. Gamma-Secretase modulators. WO2010147969A2; 2010
58. Gijsen H, Bischoff F, Zhuang W, et al. Ortho-McNeil-Janssen Pharmaceuticals, Inc., USA. Substituted benzoxazole, benzimidazole, oxazolopyridine and Imidazopyridine derivatives as gammasecretase modulators and their preparation and use for the treatment of diseases. WO2010094647A1; 2010
59. Bischoff FP, Gijsen HJM, Pieters SMA, Minne GB; Ortho-McNeil-Janssen Pharmaceuticals, Inc., USA. Preparation of substituted indazole and aza-indazole derivatives as gamma-secretase modulators. WO2010145883A1; 2010
60. Bischoff F, Berthelot D, De Cleyn M, et al. Design and synthesis of a novel series of bicyclic heterocycles as potent gamma-secretase modulators. J Med Chem 2012;55:9089-106
61. Van Brandt SFA, De Cleyn MAJ, Gijsen HJM, et al. Ortho-McNeil-Janssen Pharmaceuticals, Inc., USA. Triazole derivatives as gamma-secretase modulators and their preparation and use for the treatment of diseases. WO2011086099A1; 2011
62. Keserue GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009;8:203-12
63. Gijsen HJM, Mercken M. Gammasecretase modulators: can we combine potency with safety? Int J Alzheimers Dis 2012;2012:295207
64. De Cleyn MAJ, Van Brandt SFA, Gijsen HJM, et al. Ortho-McNeil-Janssen Pharmaceuticals, Inc., USA. Triazole derivatives as gamma-secretase modulators and their preparation and use for the treatment of diseases. WO2011086098A1; 2011
65. Baumann K, Goetschi E, Green L, et al. F. Hoffmann-La Roche AG, Switz. Preparation of phenyltriazolopyridiny limidazolylphenylamine derivatives and analogs for use as gamma-secretase modulators. WO2011092272A1; 2011
66. Boy KM, Guernon JM, Macor JE, et al. Bristol-Myers Squibb Co., USA. Preparation of fused pyrimidine compounds as modulators of beta-Amyloid production. US20120028994; 2012
67. Boy KM, Guernon JM, Macor JE, et al. Bristol-Myers Squibb Co., USA. Preparation of macrocyclic compounds fused to benzene and pyrimidine rings for the reduction of beta-Amyloid production. WO2012009309A1; 2012
68. Boy KM, Guernon JM, Macor JE, et al. Bristol-Myers Squibb Co., USA. Preparation of bicyclic pyrimidine compounds for the reduction of beta-Amyioid production. WO2012103297A1; 2012
69. Lo-Alfredsson Y, Paulsen K, Rakos L, et al. AstraZeneca AB, Swed. Preparation of pyridooxazepine derivatives for use as gamma-secretase modulators and treatment of alpha beta related pathologies, such as Alzheimer's disease. WO2010132015A1; 2010
70. Macsari I, Paulsen K, Rakos L, et al. AstraZeneca AB, Swed. Preparation of pyrido[3,2-f][l,4]oxazepine compounds and their use for treatment of Abetarelated diseases. WO2012064269A1; 2012
71. Kimura T, Doi E, Doko T, et al. Eisai R&D Management Co., Ltd., Japan. Preparation of aryl imidazole compounds and their use as beta amyloid production inhibitors. WO2010098488A1; 2010
72. Kitazawa N, Shinmyo D, Ito K, et al. Eisai R&D Management Co., Ltd., Japan. Nitrogen-containing fused heterocyclic compounds as beta-Amyloid production inhibitors and their preparation and use for the treatment diseases caused by Abeta. WO2010098487A1; 2010
73. Hasegawa D, Kitazawa N; Eisai R&D Management Co., Ltd., Japan. Preparation of 2-(imidazol-1-yl)pyrazine derivatives as inhibitors of protein amyloid-beta (Abeta). WO2010098495A1; 2010
74. Wu T, Gijsen HJM, Rombouts FJR, et al. Ortho-McNeil-Janssen Pharmaceuticals, Inc., USA. Preparation of substituted phenyltriazole derivatives and analogs for use as gamma secretase modulators associated with beta-Amyloid. WO2011006903A1; 2011
75. Koike T, Hoashi Y, Tomata Y; Takeda Pharmaceutical Co., Ltd, Japan. Preparation of Heterocyclic compounds as inhibitors for production of amyloid beta protein. WO2011007756Al; 2011
76. Koike T, Nakamura M, Tomata Y, et al. Takeda Pharmaceutical Co., Ltd, Japan. Preparation of fused triazoles for the treatment or prophylaxis of mild cognitive impairment. WO2012029991A1; 2012
77. Iwama S, Ikeda T, Kobayashi T; Dainippon Sumitomo Pharma Co., Ltd., Japan. Preparation of 4-(4- pyridinyOphenyl-substituted fused 1,2,4-triazole derivatives as inhibitors of beta-Amyloid production. WO2012057300A1; 2012
78. Kounnas MZ, Ackerman EJ, Stauderman KA, et al. NeuroGenetic Pharmaceuticals, Inc., USA. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor. WO2011057214A2; 2011
79. Wagner SL, Cheng S, Mobley WC, Tanzi RE; University of California, USA. Preparation of heterocyclic compounds and therapeutic use thereof as modulators of various amyloid beta peptide alloforms. WO2011163636A2; 2011
80. Iwama S, Nakagawa H, Kato Y, Dainippon Sumitomo Pharma Co., Ltd., Japan. Oxadiazole derivative as therapeutic agent for beta-Amyioidassociated neuropsychiatrie disorders. WO2011001931A1; 2011
81. Am Ende CW, Johnson DS, O'Donnell CJ, et al. Pfizer, Inc., USA. Preparation of heteroaryl imidazoles and heteroaryi triazoles as gamma-secretase modulators. WO2O11048525A1; 2011
82. Pettersson M, Johnson DS, Subramanyam C, et al. Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active gamma-secretase modulators. Bioorg Med Chem Lett 2012;22:2906-11
83. Am Ende CW, Fish BA, Green ME, et al. Pfizer, Inc., USA. Preparation of pyrido[1,2-A]pyrazine-1,6-dione derivatives as gamma-secretase modulators. WO2012131539A1; 2012
84. Iwama S, Kato Y, Kobayashi T, Fusano A, Dainippon Sumitomo Pharma Co., Ltd., Japan. Preparation of 4-(1H-imidazol-1-y) benzamide and (1H-imidazol-1-y) pyridinecarboxamide derivatives as beta amyloid 42 production inhibitors. WO2011059048Al; 2011
85. Koike T, Raker J; Takeda Pharmaceutical Co., Ltd, Japan. Preparation of 1-[4- (1H-imidazol-1-yl)phenyl]-1, and -pyrrolidine derivatives as inhibitors of amyloid-beta production. WO2011016559A1; 2011
86. Terauchi J, Koike T, Honda E; Takeda Pharmaceutical Co., Ltd, Japan. Preparation of piperazines and related compounds for inhibiting amyloid-beta production. WO2011002067A1; 2011
87. Kato I, Kano K; Shionogi & Co., Ltd., Japan. Preparation of lactam or benzenesulfonamide compounds as inhibitors for production of amyloid beta protein. WO2011007819A1; 2011
88. Bischoff FP, Velter Al, Van Brandt SFA, Berthelot DJ-C, Janssen Pharmaceuticals, inc., USA. Preparation of triazolylpiperazine derivatives and analogs for use as gamma-secretase modulators. WO2012126984A1; 2012
89. Baumann K, Green L, Limberg AF; Hoffmann-La Roche AG, Switz. Preparation of bridged piperidine derivatives for use as amyloid beta modulators. WO2012116965A1; 2012
90. Kobayashi N, Nishitomi A, Fuchino K; Shionogi and Co., Ltd., Japan. Preparation of indole-Amide compounds for inhibiting amyloid-beta production. JP2012107001A; 2012
91. Bronk BS, Austin WF, Creaser SP, et al. Satori Pharmaceuticals, Inc., USA. Preparation of cholestane derivatives useful for treating neurodegenerative disorders. WO2011109657A1; 2011
92. Fuller NO, Hubbs JL, Austin WF, et al. Initial optimization of a new series of gamma-secretase modulators derived from a triterpene glycoside. ACS Med Chem Lett 2012;3:908-13
93. Hubbs JL, Fuller NO, Austin WF, et al. Optimization of a natural product-based class of gamma-secretase modulators. J Med Chem 2012;55:9270-82
94. Tate B, McKee TD, Loureiro RM, et al. Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis 2012;2012: 210756Available from: http://www.fiercebiotech. com/story/satori- pharmaceuticals-shutsdown- after-failure-Alzheimers-drug/2013- 05-30
95. Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 2009;52:6752-6
96. Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 2010;1:425-49
97. Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18:4872-5
98. Pharmaceutical Research and Manufacturers of America, Medicines in development for Alzheimer's disease. 2012. Available from: http://www.phrma.org/ sites/default/files/pdf/alzheimers2012.pdf
99. Li X, Dang S, Yan C, et al. Structure of a presenilin family intramembrane aspartate protease. Nature 2013;493:56-61
100. Pozdnyakov N, Murrey HE, Crump CJ, et al. gamma-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem 2013;288:9710-20